Join Dr. Magdalena Richter, Associate Principal Scientist at AstraZeneca, as she details how her team systematically addressed this bottleneck. By benchmarking Nuclera’s eProtein Discovery™ system against standard E. coli cell-based expression, her team asked a critical question: Can a 24-hour, cell-free screen accurately predict expression success at scale?